Background. We characterized temporal trends in highly active antiretroviral therapy (HAART) initiation (1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008) among treatment-eligible persons in a community-based cohort of current and former injection drug users (IDUs) in Baltimore, Maryland.
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Temporal Trends in Highly Active Antiretroviral Therapy Initiation among Injection Drug Users in Baltimore, Maryland, 1996 Maryland, -2008 ment in reducing transmission at a population level, which has revived discussions of when therapy should be started [7] and prompted new treatment guidelines [8] . For example, an analysis of 117,000 human immunodeficiency virus (HIV)-infected patients in North America demonstrated the benefits of initiating antiretroviral therapy (ART) at CD4 + cell counts 1350 cells/ mm 3 and even 1500 cells/mm 3 , which are thresholds that have not previously been indicated for treatment [6] . Deferral of treatment until lower CD4 + cell counts were achieved (those at which treatment was recommended) was associated with substantially increased mortality. These data are reinforced by a populationlevel simulation analysis that suggests that early diagnosis and universal treatment of HIV infection can eradicate the epidemic by 2016 [9] .
Although these studies are compelling, other evi- dence reinforces the point that much work remains. Reports have suggested that even in countries with established ART programs, the majority of patients continue to initiate HAART at CD4 + cell counts well below 200 cells/mm 3 [10, 11] . IDUs stand to benefit as much if not more than other groups from earlier treatment, because IDUs experience high rates of mortality from non-AIDS-related causes [12] and a high prevalence of coinfections, including infections due to hepatitis C virus (HCV) [13] . However, IDUs have historically initiated HAART later than have other populations [14, 15] and have been associated with diminished responses [16, 17] and poorer survival [18] . If goals of universal testing and treatment are to be achieved, special efforts need to target IDUs who have historically lagged behind.
We characterized temporal trends and predictors of time to HAART initiation among treatment eligible current and former IDUs over a 12-year period (January 1996-June 2008). Understanding trends and barriers to HAART initiation in this population will inform large-scale efforts to globally improve earlier initiation of antiretroviral therapy.
METHODS

Study population.
From 1988 through 1989, 2946 IDUs in Baltimore, Maryland, were enrolled into a cohort study of the natural history of HIV (the AIDS Linked to the IntraVenous Experience [ALIVE]) study) and were followed-up semi-annually [19] . Participants were у18 years of age, free of AIDS at study entry, and acknowledged IDU within the previous 11 years. Additional recruitment occurred during [1994] [1995] 1998 , and 2000; in these recruitments, there was a requirement of more-recent IDU. Overall, 1206 HIV-positive participants were recruited; 737 (61%) were in follow-up after July 1996, when HAART became available. A total of 582 HIV-positive participants with at least 2 follow-up visits after July 1996 became eligible for HAART between 1996-2007. Eligibility was defined as the first visit after July 1996 at which CD4 + cell count decreased to !350 cells/mm 3 . Throughout the study period, HIV treatment guidelines suggested that asymptomatic HIV-infected adult patients with CD4 + cell counts !350 cells/ mm 3 should have been either considered for or recommended to initiate HAART [20] [21] [22] . Although treatment guidelines in earlier time periods recommended HAART initiation at a CD4 + cell count !500 cells/mm 3 [20, 21] , our selection of a lower CD4 + cell count threshold would only attenuate estimates of treatment delay during earlier periods. Compared with those who became eligible, those who did not become eligible were younger, were more often female, were less often African-American, and had a significantly shorter time in study (median duration, 2 years vs 3 years;
). The study was approved P p .02 by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board, and all participants provided written informed consent.
Measurements. Semi-annual data collection included standardized interviews with some components administered by interview and others collected via audio computer-assisted selfinterview (ACASI). Questions about reported HIV medications prescribed and taken, medical history, and health care use were administered by interview, whereas sensitive questions regarding drug use and other risk behaviors were administered via ACASI. All questions reflected the prior 6 months. HAART was defined as 1 of the following combinations: (1) protease inhibitor (PI) plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs), (2) nonnucleoside reverse-transcriptase inhibitor (NNRTI) plus 2 NRTIs, (3) abacavir in combination with lamivudine and zidovudine or stavudine (3 NRTIs), and (4) PI plus NNRTI plus NRTI [16] .
All participants had blood samples drawn and underwent physical examination. HIV antibodies were measured using a commercially available enzyme-linked immunosorbent assay (Genetic Systems) and were confirmed with Western blot (Dupont) according to the manufacturer's instructions. T cell subpopulations were measured using whole-blood staining methods and flow cytometry. Plasma HIV RNA levels were quantified using reverse-transcription polymerase chain reaction (Roche Molecular Systems) according to the manufacturer's specifications. The dynamic range of the assay was ∼4 logs (on a base 10 scale), and the minimal detectable HIV RNA level was 400 copies/mL. During the physical examination, participants received client-centered counseling, which included information regarding CD4
+ cell count and viral load, the interpretation of this data, and tailored risk reduction. Although there was no active referral system, participants were provided with information on HIV care locations; additional referrals were provided upon request.
Statistical analysis. Annual HAART initiation rates per 100 person-years of eligibility were calculated by dividing the number of persons who initiated HAART in a calendar year by the total person-years of eligibility within that calendar year. Date of HAART initiation was set as the visit date of the first HAART report. x 2 tests for trend were used to examine temporal trends in HAART initiation. Because of limited numbers in 1996 and 2008, data from these years were combined with data for the years 1997 and 2007, respectively. We tested for trends in treatment delay and CD4 + cell count at the time of initiation using linear regression models with calendar year as an ordinal variable.
Survival analysis methods were used to identify predictors of shorter or longer time to initiation of HAART. The time origin was date of HAART eligibility, and individuals contributed time to the analysis up to HAART initiation date or the last follow-up visit for those censored. Parametric survival models were used that assumed a log-normal distribution (accelerated failure time). These models assume the hazard function takes on a log-normal shape. The effects of covariates are expressed as time ratios (TR) as either accelerating (shortening) or decelerating (lengthening) time to HAART initiation. The overall model fit was assessed using Cox-Snell residuals. Variables considered in multivariate analysis included all those deemed a priori to be important predictors, as well as those associated with the outcome at a level of statistical sig-P ! .10 nificance. Analyses were performed using SAS, version 9.12 (SAS Institute).
RESULTS
The median age of 582 HAART-eligible participants at eligibility was 41 years (interquartile range [IQR], 36-45 years), 97% were African-American, and 75% were male (Table 1) . Fourteen percent reported heavy alcohol use, 33% reported daily IDU, and 13% were enrolled in methadone substitution programs at the time of eligibility. Sixty-two percent reported prior receipt of antiretroviral therapy, 8% had received a prior AIDS diagnosis, and the median CD4 to follow-up after being observed for a median of 2.6 years (IQR, 1.7-5.0 years) after becoming eligible, and 39 (17%) were followed up in the study for a median of 7.9 years (IQR, 4.7-10.1 years) after eligibility. There was no statistically significant trend in HAART initiation over time (
, by test for trend). Trends in treatment delay and CD4 + cell count at HAART initiation. We further characterized temporal differences in HAART initiation by calendar period of eligibility; in particular, we were interested in trends in the delay between eligibility and initiation of treatment and the degree of immune suppression at initiation (Figure 3 ). In general, there was no statistically significant trend towards improvement in CD4 + cell count over time ( for all groups). Among those who became eligible P 1 .05 before 2003, we observed substantially longer treatment delays over time. For example, among those who became eligible during the period 1996-1998, the median time from eligibility to initiation increased from 12.0 months to 133. Predictors of time to HAART initiation. In univariate analysis, compared with persons who became eligible for HAART during the period 1996-1998, those who became eligible during 1999-2002 had a significantly longer time to HAART initiation (TR, 1.18; 95% CI, 1.04-1.32), but no difference was observed among those who became eligible during [2003] [2004] [2005] [2006] [2007] (Table 2) . In multivariate analysis, calendar period of eligibility was no longer significantly associated with a longer time to HAART 
DISCUSSION
In this large cohort of current and former IDUs, we did not observe improvement in HAART initiation over a decade, which appears at least in part to be attributable to a subset of refractory IDUs who did not initiate treatment despite being eligible for several years. There were modest, although not statistically significant, suggestions that HIV-infected participants who became eligible for and initiated HAART in recent calendar years did so after less treatment delay than did those who became eligible in earlier periods. Despite this, it remains concerning that many persons initiate therapy after lengthy delays with advanced immunosuppression and that nearly one-third of individuals who recently became eligible for treatment still have not initiated therapy.
To appropriately initiate HAART, HIV-infected persons must receive an early diagnosis, promptly access care, and convince health care providers of their ability to adhere to therapy; illicit drug use may impede each of these steps. Many strategies have focused on early detection of HIV infection, including expanded voluntary counseling and testing and opt-out testing [23] , and targeted HIV testing has been suggested to improve HAART uptake among some IDUs [24] . However, our data suggest that early diagnosis alone may be inadequate. All par-ticipants in our study received biannual counseling and passive referrals for care. Despite this, a large number either initiated HAART after substantial delay or did not initiate HAART at all. These findings suggest that efforts to test and treat individuals with HIV infection need to also incorporate methods to refer and retain those individuals in care. Our data are consistent with data from the past 16 years from the Johns Hopkins HIV Clinic in Baltimore, where among persons with a history of IDU there has been an increase in the severity of immunosuppression at the time of presentation for HIV care [25] . Moreover, whereas other risk groups had shorter times between diagnosis and presentation for care in later calendar years, persons with a history of IDU had a significantly increased time between diagnosis and presentation, from a median of 378 days for the period 1990-1994 to 630 days for the period [2003] [2004] [2005] [2006] .
Treatment delay in this population was likely attributable to both health care provider reticence and participant behavior, but it is difficult to disentangle the relative contributions. Importantly, the trends parallel changes in guidelines for HAART initiation, which suggests that physicians do follow guidelines. Not surprisingly, heavy IDU was strongly associated with longer time to HAART initiation, which is consistent with prior analyses confirming the role of IDU in delayed HAART initiation during the period 1996-1998 [15] , impaired response to HAART [16] , consistent HAART use [26] , and survival in this cohort [16] . After accounting for active heavy IDU in this analysis, no other markers of stability, including homelessness, incarceration, and methadone maintenance, remained independently associated with HAART initiation, which suggests that these stability factors which have been previously shown to impact HIV infection outcomes [27] are all tied to ongoing IDU. Interestingly, a moderate frequency of IDU was not associated with longer time to HAART initiation. Some of these findings may reflect IDUs "aging out" of drug use prior to HIV disease progression and treatment eligibility. In total, these findings suggest that there is a functional group of active IDUs who can successfully initiate, maintain, and respond to HAART, which reinforces that active IDU should not be an automatic exclusion. Different strategies to promote HAART uptake may be needed, depending on the intensity of use, but all individuals should be targeted for interventions to promote early initiation. Future studies are also needed to better understand health care provider willingness to prescribe antiretroviral drugs to IDUs with different intensities of use.
It is somewhat optimistic that persons who recently became eligible initiated HAART, on average, within 6 months after eligibility. However, after accounting for heavy IDU, we did not observe any significant difference in time to initiation between calendar periods of when persons became eligible. Furthermore, one-third of the most recently eligible group had still not initiated therapy. Our data also suggest that a substantial proportion of those who initiated therapy early in recent years were prescribed inferior triple nucleoside regimens. Inferences are limited because of the small sample size in recent years, but understanding provider views on the selection of regimens for persons with a history of IDU remains important.
We were limited in this analysis, because most persons became eligible during the period 1996-1998, and many had CD4 + cell counts that decreased below 350 cells/mm 3 before HAART was available. The lack of improvement in HAART initiation over time may, at least in part, reflect a group of persons intransigent to HAART initiation. Similarly, this group appears to represent the majority of the subset with extremely prolonged delay in treatment. Further qualitative and translational research will be needed to develop novel intervention strategies to engage these individuals in care and treatment for drug dependence and HIV infection. We were further limited by the 6-month visit structure of the ALIVE study, which hinders the precision of our estimates of HAART eligibility and initiation. We did not have information on physician prescribing behaviors and therefore cannot comment on whether trends reflect patient or physician decisions. Definitions of HAART eligibility changed over the course of the study period, from treating early in 1998 (initiating treatment at a CD4 + cell count , which, if anything, would bias the results towards higher initiation rates in later periods, because the criteria in the early years were less stringent [20, 21] . Finally, generalizability of these findings may be limited, because our cohort was predominantly urban, male, and African American, and a large proportion of our cohort were ART experienced.
In conclusion, we failed to observe improved HAART initiation over time among persons eligible for treatment eligible who had a history of IDU, despite repeated counseling and referrals. Although there is suggestion of diminished treatment delay among newly eligible participants, there remain many who failed to initiate or only recently initiated HAART after lengthy delays with advanced immune suppression. Heavy IDU continues to be the major barrier to ART initiation and consistent HIV care. Interventions to address ongoing substance abuse, including programs that emphasize reductions in the intensity of IDU, may improve ART uptake in this population.
